Key result
TAT is linked to ~70% lower MI and stent thrombosis risk versus DAT when scores ≥5.
Why the study?
It is unclear how to select atrial fibrillation patients undergoing PCI who are at high thrombotic risk and might benefit from triple antithrombotic therapy over double therapy.
Does triple antithrombotic therapy reduce ischaemic events compared to double antithrombotic therapy in high-risk patients with atrial fibrillation undergoing percutaneous coronary intervention?
Observational
Does triple antithrombotic therapy reduce ischaemic events compared to double antithrombotic therapy in high-risk patients with atrial fibrillation undergoing percutaneous coronary intervention?
A novel clinical risk score can identify a small subgroup of AF patients undergoing PCI who may benefit from triple antithrombotic therapy over double therapy without an increased bleeding risk.
Answers are grounded in this paper and cite their sources.
May support risk-stratified triple therapy in high-risk AF-PCI; hypothesis-generating and requires randomized confirmation.
BACKGROUND: Current guidelines recommend treating atrial fibrillation (AF) patients who undergo percutaneous coronary intervention (PCI) with triple antithrombotic therapy (TAT) for up to one month in patients at high thrombotic risk. It is unclear how to select these high-risk patients. AIMS: The aim of this study was to identify patients at high thrombotic risk who might benefit from TAT over double antithrombotic therapy (DAT). METHODS: This study was a post hoc subanalysis of the RE-DUAL PCI trial. A Cox proportional hazards model was built by stepwise selection of plausible predictor variables for a composite ischaemic endpoint, defined as cardiovascular death, myocardial infarction (MI), stent thrombosis (ST) or ischaemic stroke. The effect of TAT versus DAT was calculated for those patients with the highest proportion of predicted thrombotic risk. A simplified risk score was constructed based on beta-coefficients. RESULTS: For 209 patients (7.7%) the composite ischaemic endpoint occurred during the first year. The simplified risk score contained six variables. In patients with a score ≥5 (n=154, 5.7%), a significant reduction in the composite of MI and ST was observed with TAT versus DAT (6.3% vs 21.0%, p=0.041), without a penalty in terms of bleeding. In patients at low thrombotic risk, a significant increase in bleeding was observed without a reduction of ischaemic events. CONCLUSIONS: Our findings support the use of DAT in the majority of patients. A small subgroup of patients might benefit from TAT and we propose a novel clinical risk score to select these patients.
No takes yet. Share an insight, caveat, or question.
Zwart et al. (2022) conducted an observational in Atrial fibrillation undergoing percutaneous coronary intervention. Triple antithrombotic therapy (TAT) vs. Double antithrombotic therapy (DAT) was evaluated on Composite of myocardial infarction and stent thrombosis in patients with risk score ≥5 (p=0.041). In patients with a novel risk score ≥5, triple antithrombotic therapy reduced the composite of MI and stent thrombosis compared to double therapy.
Synapse has enriched 10 related papers. Consider them for comparative context: